AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Anti–interleukin five (IL-5) biologics such as mepolizumab and benralizumab have shown significant efficacy in reducing ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...